Click on headlines below to download research

SDC-1801 records positive Phase Ia data
Sareum Holdings | 02/07/2024

Sareum Holdings has announced positive top-line data from the Phase Ia clinical trial for SDC-1801, its lead asset, a novel TYK2/JAK1 inhibitor targeting…

...read more

A decisive period ahead for SDC-1801
Sareum Holdings | 03/04/2024

Sareum Holdings’ H124 results highlighted the company’s swift progress for lead asset SDC-1801, since gaining regulatory approval in Australia…

...read more

Positive clinical step forward in SDC-1801
Sareum Holdings | 19/02/2024

Sareum Holdings has announced positive clinical progression for SDC-1801, its lead asset and novel TYK2/JAK1 inhibitor targeting the autoimmune space (with…

...read more